GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Neuren Pharmaceuticals NEU.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

23.84

+2.58%

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in AUD, from our data supplier.

FY2025

Net income

A$30.4m

FY2016FY2025

Free cash flow

A$125.4m

FY2016FY2025

Shareholders' equity

A$338.5m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Research and developmentA$36.4mA$33.0mA$26.8mA$12.7mA$9.5mA$7.8mA$9.9mA$6.1mA$5.1mA$13.3m
Operating incomeA$22.0mA$175.6mA$172.5m−A$1.6m−A$11.4m−A$9.5m−A$11.6mA$5.8m−A$6.7m−A$15.2m
Net incomeA$30.4mA$142.0mA$157.1mA$184,000−A$7.8m−A$9.2m−A$10.8mA$3.1mA$3.3m−A$12.0m
Diluted earnings per share0.231.091.200.00-0.06-0.08-0.110.030.03-0.15

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsA$342.9mA$409.7mA$248.0mA$43.3mA$40.1mA$25.0mA$14.4mA$26.6mA$17.9mA$6.2m
Cash and short-term investmentsA$296.1mA$222.2mA$228.5mA$40.2mA$36.8mA$24.2mA$13.8mA$23.6mA$4.7mA$5.1m
Total liabilitiesA$4.4mA$45.8mA$42.8mA$1.7mA$803,000A$753,000A$559,000A$2.0mA$1.6mA$2.0m
Debt————————A$9.1m—
Shareholders' equityA$338.5mA$363.9mA$205.2mA$41.6mA$39.3mA$24.2mA$13.8mA$24.7mA$16.4mA$4.2m
Shares outstanding133m131m131m126m129m117m103m102m98m81m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsA$125.4m−A$11.3mA$184.9mA$3.6m−A$10.0m−A$8.1m−A$11.7mA$6.4m−A$5.6m−A$12.4m
Capital spending−A$37,000−A$10,000−A$40,000−A$19,000−A$10,000−A$6,000−A$12,000−A$12,000−A$12,000−A$10,000
Free cash flowA$125.4m−A$11.3mA$184.9mA$3.6m−A$10.0m−A$8.1m−A$11.7mA$6.4m−A$5.6m−A$12.4m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
Operating incomeA$2.7mA$11.1m−A$4.0mA$160.0m−A$13.8mA$151.1mA$48.1mA$5.7m
Net incomeA$4.9mA$15.4mA$15.0mA$134.0mA$8.0mA$109.3mA$47.8mA$7.2m
Diluted earnings per share0.040.120.111.030.060.830.360.06
Cash from operationsA$8.0m−A$2.0mA$128.0mA$9.0m−A$20.0mA$140.0mA$44.0mA$9.0m
Total assetsA$340.6mA$342.9mA$331.3mA$409.7mA$228.2mA$248.0mA$97.5mA$43.3m
Cash and short-term investmentsA$286.5mA$296.1mA$299.5mA$222.2mA$213.2mA$228.5mA$85.7mA$40.2m
Shareholders' equityA$333.4mA$338.5mA$323.3mA$363.9mA$219.2mA$205.2mA$91.5mA$41.6m

Financial ratios

Data as of 3 Nov 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2011FY2010FY2009FY2008
Operating margin34.1%82.3%85.9%-4.7%-343.8%-1382.1%————
Net margin47.1%66.6%67.7%1.3%-243.8%-1282.1%————
Return on equity9.0%39.0%76.5%0.4%-19.9%-38.0%————
Return on assets8.9%34.7%63.3%0.4%-19.5%-36.8%————
Free cash flow yield4.6%-0.4%6.8%0.1%-0.4%-0.3%————
Revenue growth-69.7%-8.1%1493.7%355.2%345.9%44.8%————
Earnings growth-78.6%-9.6%85270.1%-102.4%-15.2%-15.0%————
Current ratio76.60x8.73x5.78x25.77x49.87x33.12x————
Debt to equity0.00x0.00x0.00x0.00x0.00x0.00x————
Equity ratio98.7%88.8%82.8%96.1%98.0%97.0%————
Interest coverage———-1.74x-3.02x—-782.88x-3285.49x-10.00x-593.55x
R&D as a share of sales56.3%15.5%11.5%87.3%297.7%1082.7%————
Buybacks as a share of market value-1.4%0.3%-4.0%2.3%-10.6%-13.6%————

Growth per year

Compound annual rate

3 years5 years10 years
Revenue64.4%146.0%44.1%
Net income448.9%——

Average margins

Over each period

1 year3 years5 years10 years
Operating margin71.1%70.3%65.8%55.2%
Net margin62.1%62.9%59.2%51.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings81.011.520.8—-62.4-16.3-23.546.354.5-4.5
Price to sales38.27.714.168.8152.1209.0—10.2284.317.0

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 20-to-1 reverse split · 21 Nov 2017

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.